Liver Cancer News and Research RSS Feed - Liver Cancer News and Research

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Clinical trial finds pioglitazone drug safe and effective for NASH patients

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants. [More]
Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
Drinking piping hot beverages may increase risk of esophagus tumors

Drinking piping hot beverages may increase risk of esophagus tumors

Drinking piping hot coffee, tea and the caffeine-infused beverage yerba mate probably causes cancer, the World Health Organization announced Wednesday. [More]
Portal vein hypertension diminishes after hepatitis C recovery

Portal vein hypertension diminishes after hepatitis C recovery

This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein. [More]
Disruption of SVIP protein can lead to cardiovascular, fatty liver disease

Disruption of SVIP protein can lead to cardiovascular, fatty liver disease

A UCF College of Medicine researcher has identified for the first time a tiny liver protein that when disrupted can lead to the nation's top killer -- cardiovascular disease -- as well as fatty liver disease, a precursor to cancer. [More]
Pre-procedure medication regimen could lower incidence of hospital readmission in lung caner patients

Pre-procedure medication regimen could lower incidence of hospital readmission in lung caner patients

Researchers at the University of Cincinnati College of Medicine have found that putting liver cancer patients on a medication regimen prior to undergoing a certain treatment could lead to shorter hospital stays and less chance for readmission due to complications. [More]
New drug-capture device can soak up chemotherapy drugs to limit toxicity

New drug-capture device can soak up chemotherapy drugs to limit toxicity

Doctors have a powerful arsenal of cancer-fighting chemotherapy drugs to choose from, though a key challenge is to better target these drugs to kill tumors while limiting their potentially harmful side effects. [More]
Study shows no higher cancer risk in patients undergoing spinal fusion surgery with rhBMP

Study shows no higher cancer risk in patients undergoing spinal fusion surgery with rhBMP

Adding to previous evidence, a study based on a statewide cancer database shows no increase in cancer risk in patients undergoing spinal fusion surgery with the bone-promoting growth factor recombinant human bone morphogenetic protein (rhBMP). The study appears in Spine, published by Wolters Kluwer. [More]
Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases. [More]
Study finds increased risk of mortality in black, Hispanic cancer patients

Study finds increased risk of mortality in black, Hispanic cancer patients

Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented at the American Society for Clinical Oncology Annual Meeting 2016. [More]
Scientists debate role of AAV in causing hepatocellular carcinoma

Scientists debate role of AAV in causing hepatocellular carcinoma

Liver cancer can be triggered by mutations in cancer driver genes resulting from the insertion of adeno-associated virus (AAV) vectors used to deliver therapeutic genes, although this tumor-inducing role of AAV remains highly controversial. [More]
Researchers discover new potential treatment target for liver cancer

Researchers discover new potential treatment target for liver cancer

Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer. [More]
High levels of p62 protein in liver linked to cancer recurrence

High levels of p62 protein in liver linked to cancer recurrence

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. [More]
Research sheds light on potential impact of HCV treatment in preventing virus transmission

Research sheds light on potential impact of HCV treatment in preventing virus transmission

An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV). [More]
High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats. [More]
Clinical study shows sitagliptin drug not effective in treating NAFLD

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. [More]
MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer. [More]
Increasing number of sickest liver transplant candidates delisted from wait list, study finds

Increasing number of sickest liver transplant candidates delisted from wait list, study finds

The sickest liver transplant candidates should be first in line when a donor liver becomes available, but transplant centers are increasingly removing these individuals from the waiting list, considering them "too sick to transplant," an analysis of nationwide transplant data finds. The study appears online as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication. [More]
Advertisement